> Details

Gordon, Richard; Albornoz, Eduardo A.; Christie, Daniel C.; Langley, Monica R.; Kumar, Vinod; Mantovani, Susanna; Robertson, Avril A. B.; Butler, Mark S.; Rowe, Dominic B.; O’Neill, Luke A.; Kanthasamy, Anumantha G.; Schroder, Kate; Cooper, Matthew A.; Woodruff, Trent M.

Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice
  • Contributor: Gordon, Richard; Albornoz, Eduardo A.; Christie, Daniel C.; Langley, Monica R.; Kumar, Vinod; Mantovani, Susanna; Robertson, Avril A. B.; Butler, Mark S.; Rowe, Dominic B.; O’Neill, Luke A.; Kanthasamy, Anumantha G.; Schroder, Kate; Cooper, Matthew A.; Woodruff, Trent M.
  • imprint: American Association for the Advancement of Science (AAAS), 2018
  • Published in: Science Translational Medicine
  • Language: English
  • DOI: 10.1126/scitranslmed.aah4066
  • ISSN: 1946-6234; 1946-6242
  • Origination:
  • Footnote:
  • Description: <jats:p>Oral treatment with a brain-penetrant NLRP3 inhibitor has protective effects in preclinical models of Parkinson’s disease.</jats:p>